ストックスクリーナーアプリを入手
98.66
0.36%
0.35
アフターアワーズ：
98.66
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Behavioral Patterns of RYTM and Institutional Flows - news.stocktradersdaily.com
RYTM Looks 21.0% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
Canada approves first targeted treatment for obesity caused by brain injury - Stock Titan
Rhythm Pharmaceuticals (RYTM): Analyst Consensus Points To 41.84% Upside Potential - DirectorsTalk Interviews
ETFs Investing in Rhythm Pharmaceuticals, Inc. Stocks - TradingView
Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform - Yahoo Finance
J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating - Moomoo
RHYTHM Pharmaceuticals CEO David P. Meeker Executes Option Exercise and Sells 50,000 Shares - Kalkine Media
Rhythm Pharmaceuticals (RYTM) CEO sells 50,000 shares under preset plan - Stock Titan
RYTM Assumes Outperform by Leerink Partners -- Price Target Anno - GuruFocus
Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Exploring a 33.88% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - manilatimes.net
Rhythm Pharmaceuticals Announces New Data Presentations at - GlobeNewswire
French children showed lower body-size scores on a rare-obesity drug - Stock Titan
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 36.45% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
An AI drug specialist zeroes in on rare forms of obesity - BioPharma Dive
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga
Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth - AD HOC NEWS
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$6.62 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) CFO sells 62,774 shares in planned trade - Stock Titan
Rhythm (NASDAQ: RYTM) officer files Rule 144 stock sale notice - Stock Titan
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Rhythm Pharmaceuticals (RYTM): Investor Outlook on a 30.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc. (RYTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
RHYTHM PHARMACEUTICALS, INC. : DEUTSCHE BANK INITIATES COVERAGE WITH HOLD RATING AND TARGET PRICE $120 - webull.com
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story - sahmcapital.com
Rhythm Pharmaceuticals Gains Japan Approval For IMCIVREE In Hypothalamic Obesity - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run - Yahoo Finance
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Biotechnology Innovator Seeks 28.67% Upside with Breakthrough Therapies - DirectorsTalk Interviews
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can - Yahoo Finance
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm (RYTM) Chart: Adds 0.99% to Close at $110.00; Technical Setup - careplusvn.com
TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan
Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock - Investing.com
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.com - Investing.com India
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock - Investing.com
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):